Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
<p>SNP ID.</p>
Tallennettuna:
| Päätekijä: | Francesca Orzan (15055579) (author) |
|---|---|
| Muut tekijät: | Francesca De Bacco (15055582) (author), Elisabetta Lazzarini (15055585) (author), Giovanni Crisafulli (15055588) (author), Alessandra Gasparini (15019568) (author), Angelo Dipasquale (15055591) (author), Ludovic Barault (15030747) (author), Marco Macagno (15030744) (author), Pasquale Persico (15055594) (author), Federico Pessina (15055597) (author), Beatrice Bono (15055600) (author), Laura Giordano (15055603) (author), Pietro Zeppa (15055606) (author), Antonio Melcarne (15055609) (author), Paola Cassoni (15055612) (author), Diego Garbossa (15055615) (author), Armando Santoro (15034235) (author), Paolo M. Comoglio (15055618) (author), Stefano Indraccolo (15027102) (author), Matteo Simonelli (15055621) (author), Carla Boccaccio (15055624) (author) |
| Julkaistu: |
2025
|
| Aiheet: | |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Samankaltaisia teoksia
-
Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Tekijä: Francesca Orzan (15055579)
Julkaistu: (2025) -
Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Tekijä: Francesca Orzan (15055579)
Julkaistu: (2025) -
Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Tekijä: Michael Kilian (16697663)
Julkaistu: (2025) -
Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Tekijä: Michael Kilian (16697663)
Julkaistu: (2025) -
Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Tekijä: Michael Kilian (16697663)
Julkaistu: (2025)